Niven Mehra

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi et al. · New England Journal of Medicine · 2020 · 2.1K citations · Full text

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin et al. · NEJM Evidence · 2022 · 357 citations

Urology, Genitourinary Cancer, Medicine +8

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

Johann S. de Bono, Niven Mehra, Giorgio V. Scagliotti et al. · The Lancet Oncology · 2021 · 269 citations · Full text

Urology, Genitourinary Cancer, Medicine +6

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

Fred Saad, Noel W. Clarke, Mototsugu Oya et al. · The Lancet Oncology · 2023 · 256 citations · Full text

Urology, Oncology, Genitourinary Cancer +8

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

Daphne van der Velden, Louisa R. Hoes, Hanneke van der Wijngaart et al. · Nature · 2019 · 252 citations · Full text

Drug Repositioning, Oncology, Preclinical Drug Evaluation +11